antineoplaston A10

also known as Atengenal · A10

Developed for: non-Hodgkin lymphoma · brain stem glioma · female breast carcinoma · brain cancer · brain glioblastoma · low-grade astrocytoma · prostate cancer · adrenal cortex carcinoma
+45 more
· adult oligodendroglioma · anaplastic astrocytoma · brain glioma · brain neoplasm · cancer of unknown primary site · central nervous system neoplasm · childhood central nervous system primitive neuroectodermal neoplasm · colon adenocarcinoma · colon carcinoma · cutaneous neuroendocrine carcinoma · diffuse intrinsic pontine glioma · ependymoma · esophageal adenocarcinoma · gastric cancer · head and neck cancer · high grade astrocytic tumor · kidney cancer · liver cancer · lung carcinoma · malignant mesothelioma · mantle cell lymphoma · meningioma · metastatic melanoma · metastatic prostate carcinoma · mixed glioma · neuroblastoma · non-small cell lung carcinoma · optic pathway glioma · ovarian carcinoma · pancreas disorder · pancreatic endocrine carcinoma · pituitary tumor · plasma cell myeloma · primary central nervous system lymphoma · primitive neuroectodermal tumor · prostate adenocarcinoma · refractory malignant neoplasm · rhabdoid tumor · small cell lung carcinoma · small intestine cancer · soft tissue sarcoma · urinary bladder carcinoma · uterine cancer · vulvar carcinoma · Waldenstrom macroglobulinemia
Investigated by: Burzynski Research Institute

Trials 64 · a red edge is where a trial was stopped

today NCT02864888 · Ph 3 NCT02887040 · Ph 3 NCT02742883 · Ph 2 NCT02988726 · Ph 2 NCT00003512 · Ph 2 NCT00003483 · Ph 2 NCT00003498 · Ph 2 NCT00003522 · Ph 2 NCT00003513 · Ph 2 NCT00003515 · Ph 2 NCT00003534 · Ph 2 NCT00003524 · Ph 2 NCT00003458 · Ph 2 NCT00003453 · Ph 2 NCT00003497 · Ph 2 NCT00003457 · Ph 2 NCT00003468 · Ph 2 NCT00003477 · Ph 2 NCT00003521 · Ph 2 NCT00003525 · Ph 2 NCT00003487 · Ph 2 NCT00003472 · Ph 2 NCT00003489 · Ph 2 NCT00003452 · Ph 2 NCT00003460 · Ph 2 NCT00003492 · Ph 2 NCT00003485 · Ph 2 NCT00003531 · Ph 2 NCT00003501 · Ph 2 NCT00003511 · Ph 2 NCT00003509 · Ph 2 NCT00003516 · Ph 2 NCT00003520 · Ph 2 NCT00003495 · Ph 2 NCT00003494 · Ph 2 NCT00003491 · Ph 2 NCT00003526 · Ph 2 NCT00003454 · Ph 2 NCT00003471 · Ph 2 NCT00003459 · Ph 2 NCT00003476 · Ph 2 NCT00003473 · Ph 2 NCT00003470 · Ph 2 NCT00003474 · Ph 2 NCT00003500 · Ph 2 NCT00003508 · Ph 2 NCT00003496 · Ph 2 NCT00003499 · Ph 2 NCT00003532 · Ph 2 NCT00003533 · Ph 2 NCT00003475 · Ph 2 NCT00003469 · Ph 2 NCT00003537 · Ph 2 NCT00003456 · Ph 2 NCT00003535 · Ph 2 NCT00003530 · Ph 2 NCT00003479 · Ph 2

1965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 262 trials
Phase 2	NCT02742883	Apr 2016 → Mar 2028	diffuse intrinsic pontine glioma	Burzynski Research Institute	Suspended	No outcome recorded
Phase 2	NCT02988726	Mar 1999 → Aug 2001	central nervous system neoplasm	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003512	Feb 1999 → Apr 2000	Waldenstrom macroglobulinemia	Burzynski Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT00003483	Jun 1998 → Mar 2004	meningioma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003498	Oct 1997 → Feb 2007	non-Hodgkin lymphoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003522	Aug → Dec 1997	small intestine cancer	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003513	Dec 1996 → Mar 1999	neuroblastoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003515	Dec 1996 → Jan 1997	primitive neuroectodermal tumor	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003534	Oct 1996 → Feb 1997	prostate cancer	Burzynski Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT00003524	Oct 1996 → Aug 1998	gastric cancer	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003458	Sep 1996 → Sep 2014	brain neoplasm	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003453	Aug 1996 → Jul 2011	adrenal cortex carcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003497	Aug 1996 → Feb 1998	non-small cell lung carcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003457	Jul 1996 → Feb 2012	refractory malignant neoplasm	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003468	Jul 1996 → Jul 2004	low-grade astrocytoma	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003521	Jun 1996 → Aug 2003	soft tissue sarcoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003525	Jun 1996 → Jan 1998	uterine cancer, vulvar carcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003477	Jun 1996 → May 2008	optic pathway glioma	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003487	May 1996 → Apr 2001	esophageal adenocarcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003489	May 1996 → Apr 1998	head and neck cancer	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003452	May 1996 → May 1998	urinary bladder carcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003472	May 1996 → Sep 2007	adult oligodendroglioma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003492	Apr 1996 → Dec 2000	—	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003485	Apr 1996 → May 2003	colon carcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003531	Apr 1996 → Jul 2005	pancreas disorder	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003501	Apr 1996 → Jul 2003	non-Hodgkin lymphoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003511	Apr 1996 → Oct 1999	plasma cell myeloma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003460	Apr 1996 → Feb 2005	childhood central nervous system primitive neuroectodermal neoplasm	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003509	Mar 1996 → Feb 2005	metastatic melanoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003516	Mar 1996 → Mar 2004	prostate cancer	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003520	Mar 1996 → Jan 2005	kidney cancer	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003495	Mar 1996 → Nov 2003	—	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003494	Mar 1996 → May 2002	lung carcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003491	Mar 1996 → Jul 1998	—	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003526	Mar 1996 → Feb 2005	cancer of unknown primary site	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003454	Mar 1996 → Dec 2002	female breast carcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003474	Mar 1996 → Jun 2003	brain glioblastoma	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003500	Mar 1996 → Jun 2000	non-Hodgkin lymphoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003508	Mar 1996 → Apr 2005	malignant mesothelioma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003496	Mar 1996 → Feb 2004	small cell lung carcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003499	Mar 1996 → Sep 2003	non-Hodgkin lymphoma	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003532	Mar 1996 → Oct 2002	ovarian carcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003471	Mar 1996 → Jul 2003	low-grade astrocytoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003459	Mar 1996 → Sep 2007	brain stem glioma	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003476	Mar 1996 → Jan 2012	brain cancer	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003473	Mar 1996 → Aug 2007	mixed glioma	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003470	Mar 1996 → Dec 2008	anaplastic astrocytoma	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003533	Feb 1996 → Dec 1999	metastatic prostate carcinoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003475	Feb 1996 → May 2011	brain cancer	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003469	Feb 1996 → May 2003	rhabdoid tumor	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003537	Apr 1995 → Oct 2008	brain glioma	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003456	Mar 1995 → Dec 2004	brain glioblastoma	Burzynski Research Institute	Completed	No outcome recorded
Phase 2	NCT00003535	Apr 1994 → Jan 1998	high grade astrocytic tumor	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003530	Mar 1977 → Oct 1999	liver cancer	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003479	Jul 1966 → Oct 2000	ependymoma	Burzynski Research Institute	Terminated	No outcome recorded
Phase 2	NCT00003455	—	female breast carcinoma	Burzynski Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT00003486	—	colon adenocarcinoma	Burzynski Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT00003502	—	mantle cell lymphoma	Burzynski Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT00003505	—	primary central nervous system lymphoma	Burzynski Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT00003517	—	prostate adenocarcinoma	Burzynski Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT00003514	—	cutaneous neuroendocrine carcinoma, pancreatic endocrine carcinoma, pituitary tumor	Burzynski Research Institute	Withdrawn	No outcome recorded
Phase 2	NCT00003536	—	female breast carcinoma	Burzynski Research Institute	Withdrawn	No outcome recorded

Phase 32 trials
Phase 3	NCT02864888	Jun 2027 → Dec 2029 expected	brain stem glioma	Burzynski Research Institute	Not yet recruiting	No outcome recorded
Phase 3	NCT02887040	Oct 2025 → Jun 2026 overdue	brain stem glioma	Burzynski Research Institute	Not yet recruiting	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 65 sources stand behind the page.

Field	Value	Cited text
Known as	antineoplaston A10	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003514 ↗ 7 NCT00003485 ↗ NCT00003502 ↗ NCT00003517 ↗ NCT00003486 ↗ NCT00003455 ↗ NCT00003536 ↗ NCT00003505 ↗
Known as	A10	“The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals.” NCT00003485 ↗ 40 “A10 (Atengenal); AS2-1 (Astugenal)ANP” NCT00003533 ↗ “A10 (Atengenal); AS2-1 (Astugenal)ANP” NCT00003526 ↗ “A10 (Atengenal); AS2-1 (Astugenal)ANP” NCT00003534 ↗ “A10 (Atengenal); AS2-1 (Astugenal)ANP” NCT00003453 ↗ “A10 (Atengenal); AS2-1 (Astugenal)ANP” NCT00003499 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003496 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003489 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003524 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003457 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003525 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003522 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003495 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003454 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003530 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003531 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003501 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003513 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003468 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT02742883 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003520 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT02988726 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003470 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003492 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003456 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003508 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003516 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003532 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003483 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003515 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003498 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003477 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003511 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003471 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003487 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003476 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003512 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003500 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003474 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003452 ↗ “A10 (Atengenal); AS2-1 (Astugenal)” NCT00003475 ↗
Known as	Atengenal	“A10 (Atengenal); AS2-1 (Astugenal)” NCT00003475 ↗ 55 NCT00003471 ↗ NCT00003497 ↗ NCT00003511 ↗ NCT00003458 ↗ NCT00003472 ↗ NCT00003473 ↗ NCT00003512 ↗ NCT00003474 ↗ NCT00003513 ↗ NCT00003495 ↗ NCT02864888 ↗ NCT00003476 ↗ NCT02988726 ↗ NCT00003500 ↗ NCT00003525 ↗ NCT00003477 ↗ NCT00003501 ↗ NCT00003494 ↗ NCT00003522 ↗ NCT00003499 ↗ NCT00003515 ↗ NCT00003457 ↗ NCT00003524 ↗ NCT00003470 ↗ NCT00003509 ↗ NCT00003479 ↗ NCT00003459 ↗ NCT00003498 ↗ NCT00003526 ↗ NCT00003452 ↗ NCT00003483 ↗ NCT00003516 ↗ NCT00003530 ↗ NCT00003460 ↗ NCT00003453 ↗ NCT00003508 ↗ NCT00003468 ↗ NCT00003531 ↗ NCT00003532 ↗ NCT02887040 ↗ NCT00003496 ↗ NCT00003487 ↗ NCT00003489 ↗ NCT00003454 ↗ NCT00003491 ↗ NCT00003492 ↗ NCT00003533 ↗ NCT00003456 ↗ NCT00003520 ↗ NCT00003469 ↗ NCT00003537 ↗ NCT02742883 ↗ NCT00003521 ↗ NCT00003535 ↗ NCT00003534 ↗
Action	Inhibit	“Antineoplastons may inhibit the growth of cancer cells.” NCT00003486 ↗
Modality	Small molecule	— CHEMBL1980825 ↗
Route	Intravenous	“by IV infusion” NCT00003452 ↗